More M&A Deals Could Boost Biotech ETFs

As drug providers shift away from blockbuster drugs, the biotechnology sector, along with related exchange traded funds, will be supported by the next wave of specialized or targeted drugs. For instance, Amgen (NasdaqGS: AMGN) this week announced a deal to acquire genetic sequencing firm Decode for...